FindTrial
Sign In

A study on the pain reducing effect of terminalia chebula.

â??A randomized, double blind, placebo controlled, cross over study to evaluate the analgesic activity of Terminalia chebula in healthy human participants using thermal pain modelsâ??.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/10/005106
Enrollment
24
Registered
2014-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Terminalia chebula capsules -500mg: Single dose of 2 capsules of Terminalia chebula 500mg each given orally 3 hours prior to the test. total duration of trial:3 months Control Intervent

Sponsors

NIZAMS INSTITUTE OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Healthy male participants aged 18 â?? 45yr, with a body mass index (BMI) 19.5 â?? 25.9 kg/m2 will be included in the study. • The participants having pain tolerance time between 30 sec and 180 sec with short level and high heat intensity will be included into the study. • Patients who will provide written informed consent to participate in the study. • Able to perform the test, as per protocol procedure • No history of diabetes ,hypertension, GIT disorders

Exclusion criteria

Exclusion criteria: • Uncooperative subjects. • Prior wounds or fractures on the tested extremity • Any significant abnormality identified on physical examination or laboratory tests. • Smokers, Alcoholics, drug abusers (amphetamines, cocaine, sympathomimetics, systemic glucocorticoids, anabolic steroids, will be not included in the study. • Participants using other anti oxidants and over the counter medications. • Participants using other non-steroidal anti-inflammatory drugs in the past 2 weeks. • Use of other investigational drugs at the time of enrollment, or within 3 months prior to this study. • History of hypersensitivity to the study drug

Design outcomes

Primary

MeasureTime frame
Increase in the pain threshold and tolerance time compared to baseline.Timepoint: PAIN THRESHOLD and PAIN TOLERANCE AT 4 Time points 1. Pre-drug(baseline) 2. 45 minutes post-drug 3. 90 minutes post-drug 4. 180 minutes post-drug—

Secondary

MeasureTime frame
Safety and tolerability of Terminalia chebula in healthy human participantsTimepoint: AT 3 Time points 1. 45 minutes post-drug 2. 90 minutes post-drug 3. 180 minutes post-drug—

Countries

India

Contacts

Public ContactCHIRANJEEVI UDAY KUMAR

Nizams Institute of Medical Sciences

ushapingali@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026